RY

170.48

-0.07%↓

TD

94.35

+0.14%↑

BMO

131.66

+1.38%↑

BNS

74.33

+0.84%↑

CM

91.64

+1.09%↑

RY

170.48

-0.07%↓

TD

94.35

+0.14%↑

BMO

131.66

+1.38%↑

BNS

74.33

+0.84%↑

CM

91.64

+1.09%↑

RY

170.48

-0.07%↓

TD

94.35

+0.14%↑

BMO

131.66

+1.38%↑

BNS

74.33

+0.84%↑

CM

91.64

+1.09%↑

RY

170.48

-0.07%↓

TD

94.35

+0.14%↑

BMO

131.66

+1.38%↑

BNS

74.33

+0.84%↑

CM

91.64

+1.09%↑

RY

170.48

-0.07%↓

TD

94.35

+0.14%↑

BMO

131.66

+1.38%↑

BNS

74.33

+0.84%↑

CM

91.64

+1.09%↑

Search

Hercules Capital Inc

Open

SectorFinanciën

18.93 0.58

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.67

Max

18.97

Belangrijke statistieken

By Trading Economics

Inkomsten

61M

119M

Verkoop

89M

169M

K/W

Sectorgemiddelde

10.764

25.743

Dividendrendement

8.56

Winstmarge

70.164

Werknemers

100

EBITDA

18M

120M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+6.48% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

8.56%

3.67%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

139M

3.4B

Vorige openingsprijs

18.35

Vorige sluitingsprijs

18.93

Nieuwssentiment

By Acuity

50%

50%

168 / 526 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Hercules Capital Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 dec 2025, 22:20 UTC

Belangrijke Marktbewegers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dec 2025, 17:31 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dec 2025, 16:30 UTC

Belangrijke Marktbewegers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dec 2025, 15:19 UTC

Belangrijke Marktbewegers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dec 2025, 15:17 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dec 2025, 14:37 UTC

Belangrijke Marktbewegers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1 jan 2026, 23:35 UTC

Marktinformatie

Gold Rises Amid Geopolitical Risks -- Market Talk

1 jan 2026, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1 jan 2026, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Sold Stake in JV to Tata Steel

1 jan 2026, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 jan 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dec 2025, 20:40 UTC

Marktinformatie

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dec 2025, 20:22 UTC

Marktinformatie

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dec 2025, 19:50 UTC

Marktinformatie

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dec 2025, 19:31 UTC

Marktinformatie

Precious Metals Cap Off Record Runs -- Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dec 2025, 17:17 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dec 2025, 17:16 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

31 dec 2025, 17:00 UTC

Acquisities, Fusies, Overnames

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dec 2025, 15:57 UTC

Acquisities, Fusies, Overnames

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dec 2025, 15:54 UTC

Marktinformatie

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dec 2025, 15:02 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dec 2025, 14:40 UTC

Acquisities, Fusies, Overnames

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dec 2025, 14:20 UTC

Marktinformatie

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dec 2025, 13:46 UTC

Marktinformatie

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Peer Vergelijking

Prijswijziging

Hercules Capital Inc Prognose

Koersdoel

By TipRanks

6.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.04 USD  6.48%

Hoogste 24 USD

Laagste 18 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hercules Capital Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technische score

By Trading Central

17.41 / 17.93Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

168 / 526 Rangschikking in Financiën

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hercules Capital Inc

Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, SaaS Finance, energy technology, sustainable
help-icon Live chat